Left ventricular assist devices in heart failure.
End-stage heart failure is an ever-growing and devastating disease. The median survival for patients with heart failure on ionotropic support alone is a meager 6 months. Historically, the only option for these patients was to be listed for heart transplantation. Out of medical necessity, the idea of left ventricular assist device (LVAD) as a bridge to transplantation was born. Since their approval by the US FDA, LVADs have quadrupled the survival in patients with heart failure. The increase in survival has also been accompanied by decreased perioperative morbidity, better biocompatibility and longer device life over first-generation LVADs. Undoubtedly, LVADs have changed the landscape of heart failure treatment and will continue to do so in the foreseeable future. In this review, we will highlight the landmark studies that have established LVADs as a therapeutic option for heart failure, as well as reviewing the current LVADs available and speculating on the advancements that will be made in the upcoming years.
Division of Cardiac Surgery, The Ohio State University, N-831 Doan Hall, 410 W. 10th Avenue, Columbus, OH, USA.
Ahmet
A
Kilic
Gorav
G
Ailawadi
D001672:Biocompatible Materials; D018795:Device Approval; D006333:Heart Failure / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D006353:Heart-Assist Devices; D006801:Humans; D015996:Survival Rate; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D001672:Biocompatible Materials